NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity Shares under NATCO Employee Stock Option Schemes, 2016 & 2017 and grant of options under Natco Employee Stock Option Scheme 2017. Natco Pharma Ltd - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificates Natco Pharma Ltd - 524816 - Shareholding for the Period Ended December 31, 2019
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg.74(5) of SEBI (DP) Regulations, 2015 NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of LOSS of Share Certificates Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO files ANDA for Trifluridine/ Tipiracil Hydrochloride Tablets for the USA market Taiho Pharmaceuticals moves US court against Natco on generic
Taiho Pharmaceutical, a Japanese pharmaceuticals company and its group company have moved a US court against Natco Pharma, alleging that the Indian NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for VCN Family Pvt Trust & Sau Family Trust